Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Total Non-Current Liabilities data on file, last reported at $332.6 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $332.6 million, up 18.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $332.6 million (up 18.59% YoY), and the FY2025 annual result was $341.0 million, up 28.84% from the prior year.
• Total Non-Current Liabilities slipped to $332.6 million in Q1 2026 per AKBA's latest filing, from $341.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $436.1 million in Q1 2022 and troughed at $246.0 million in Q1 2024.
• A 5-year average of $307.4 million and a median of $283.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities tumbled 35.04% in 2023, then rose 28.84% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $350.1 million in 2022, then retreated by 22.22% to $272.3 million in 2023, then fell by 2.8% to $264.7 million in 2024, then advanced by 28.84% to $341.0 million in 2025, then decreased by 2.45% to $332.6 million in 2026.
• Business Quant data shows AKBA's Total Non-Current Liabilities at $332.6 million in Q1 2026, $341.0 million in Q4 2025, and $317.4 million in Q3 2025.